STE insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Karen Burton Sr. Vice Pres., CFO	228	n/a	1.7%	13K	Oct 1, 2026	Oct 5, 2026

What stands out

Three officers sold more than 25% of vested holdings: John Zangerle (49% of holdings, $4.3M, 7.0% under a disclosed plan), Julia Madsen (47% of holdings, $1.3M, none under a disclosed plan) and Renato Tamaro (70% of holdings, $1.3M, none under a disclosed plan).John Zangerle: largest sale, Nov 11, 2025 · Julia Madsen: largest sale, Nov 21, 2025 · Renato Tamaro: largest sale, Nov 18, 2025

Three insiders sold shares but ended with larger stakes, because more shares came in than were sold: Mohsen Sohi (sold 4.1K, 18% of starting holdings; 7.8K added), Daniel Carestio (sold 4.4K, 8.7% of starting holdings; 24K added) and Richard Breeden (sold 1.5K, 2.3% of starting holdings; 3.8K added).Mohsen Sohi: largest sale, Aug 12, 2026 · Daniel Carestio: largest sale, Jun 4, 2026 · Richard Breeden: largest sale, Jun 2, 2026

Percentages cover 13 of 19 officers and directors. 6 are left out

Left out: Kenneth Kohler (holdings couldn't be fully reconciled); Nirav Shah (most holdings were last confirmed in 2021); Paul Martin, Esther Alegria, Louis Shapiro and Pierre Boulud (held no vested shares at the start).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.

SoldRest of starting stakeAdded during the period

John Zangerle

Sr. VP, Gen Counsel, and Sec.

Sold 49%, but 15K shares were added (mostly vesting), so the stake grew

49% · $4.3M7% planned

Julia Madsen

Sr. VP and GM, Life Sciences

Sold 47%, but 5K shares were added (mostly vesting), so the stake grew

47% · $1.3MNo plan disclosed

Renato Tamaro

V.P. & Corporate Treasurer

70% · $1.3MNo plan disclosed

Mohsen Sohi

Director

Sold 18%, but 7.8K shares were added (mostly vesting), so the stake grew

18% · $957KNo plan disclosed

Daniel Carestio

President and CEO, Director

8.7% · $947KDisclosed plan

All 7 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosed

Common questions

Is the Steris CEO selling stock?

Yes. Daniel Carestio sold 4.4K shares ($947K, 8.7% of starting holdings) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Steris insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 13% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 87% had no disclosed plan. A trading plan schedules sales in advance.

Are any Steris insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did Steris insiders sell?

About 14% overall. As a group they ended with more shares than they started with. The biggest individual seller, John Zangerle, sold shares equal to 49% of starting holdings, but more shares were added, so the stake grew. That covers the 12 months to Oct 8, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold7 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
John Zangerle Sr. VP, Gen Counsel, and Sec.	$4.3M 16K shares	49%	7% under a disclosed plan
Julia Madsen Sr. VP and GM, Life Sciences	$1.3M 5K shares	47%	No plan disclosed
Renato Tamaro V.P. & Corporate Treasurer	$1.3M 5K shares	70%	No plan disclosed
Mohsen Sohi Director	$957K 4.1K shares	18%	No plan disclosed
Daniel Carestio President and CEO, Director	$947K 4.4K shares	8.7%	Disclosed plan
Cynthia Feldmann Director	$735K 3.1K shares	33%	No plan disclosed
Richard Breeden Director	$310K 1.5K shares	2.3%	No plan disclosed

The full ownership picture18 of 19 insiders fully reconciled · 14 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 8, 2025

Sold

Held Oct 8, 2026

Still held

Richard Breeden

Director

64K

−1.5K

66K

+3.6%

Vesting, gifts, unvested awards and holding lines for Richard Breeden

+3.8Kshares vested or exercised

0gifted (net of own trusts)

20K → 20Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	36,664	38,964
Fund and its General Partner	Ordinary Shares	27,242	27,242

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,681	$239.68	Aug 8, 2034	$0
1,704	$242.85	Aug 8, 2035	$0

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Daniel Carestio

President and CEO, Director

51K

−4.4K

64K

+25%

Vesting, gifts, unvested awards and holding lines for Daniel Carestio

0shares vested or exercised

0gifted (net of own trusts)

−6.8Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	51,096	63,647

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
81,544	$251.34	Jun 4, 2034	$0
63,328	$267.66	Jun 3, 2035	$0
82,740	$230.74	Jun 2, 2036	$417K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Michael Tokich

An owner entity could not be identified from the footnotes.

Sr. Vice Pres., CFO

47K

no sales

Vesting, gifts, unvested awards and holding lines for Michael Tokich

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

An owner entity could not be identified from the footnotes.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	43,891	43,891
Unresolved (see footnote)	Ordinary Shares	3,592	3,592

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
21,720	$251.34	Jun 4, 2034	$0
7,908	$267.66	Jun 3, 2035	$0

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

John Zangerle

Sr. VP, Gen Counsel, and Sec.

34K

−16K

35K

+4.7%

Vesting, gifts, unvested awards and holding lines for John Zangerle

+15Kshares vested or exercised

0gifted (net of own trusts)

−1.4Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	33,669	35,259

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,684	$251.34	Jun 4, 2034	$0
13,360	$267.66	Jun 3, 2035	$0
15,200	$230.74	Jun 2, 2036	$77K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Mohsen Sohi

Director

22K

−4.1K

24K

+8.7%

Vesting, gifts, unvested awards and holding lines for Mohsen Sohi

+7.8Kshares vested or exercised

0gifted (net of own trusts)

−1.8Kwithheld by the company for taxes

7.8K → 9Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	22,361	24,305

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,197	$239.68	Aug 8, 2034	$0
2,226	$242.85	Aug 8, 2035	$0
1,099	$238.91	Aug 10, 2036	$0

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Cary Majors

An owner entity could not be identified from the footnotes.

SVP and President, Healthcare

13K

17K

no sales

Vesting, gifts, unvested awards and holding lines for Cary Majors

0shares vested or exercised

0gifted (net of own trusts)

−835withheld by the company for taxes

none reportedunvested awards, start → end

An owner entity could not be identified from the footnotes.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	13,427	17,338
Unresolved (see footnote)	Ordinary Shares	67	67

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,200	$251.34	Jun 4, 2034	$0
10,392	$267.66	Jun 3, 2035	$0
16,548	$230.74	Jun 2, 2036	$83K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Mary Fraser

SVP & Chief HRO

13K

14K

no sales

Vesting, gifts, unvested awards and holding lines for Mary Fraser

0shares vested or exercised

0gifted (net of own trusts)

−2.2Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	12,882	13,716

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,456	$251.34	Jun 4, 2034	$0
8,904	$267.66	Jun 3, 2035	$0
10,492	$230.74	Jun 2, 2036	$53K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Julia Madsen

Sr. VP and GM, Life Sciences

11K

−5K

12K

+14%

Vesting, gifts, unvested awards and holding lines for Julia Madsen

+5Kshares vested or exercised

0gifted (net of own trusts)

−769withheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	10,710	12,257

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,336	$251.34	Jun 4, 2034	$0
7,100	$267.66	Jun 3, 2035	$0
8,080	$230.74	Jun 2, 2036	$41K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Cynthia Feldmann

An owner entity could not be identified from the footnotes.

Director

9.4K

−3.1K

9.4K

100%

Vesting, gifts, unvested awards and holding lines for Cynthia Feldmann

+3.1Kshares vested or exercised

0gifted (net of own trusts)

8.1K → 8.6Kunvested awards, start → end

An owner entity could not be identified from the footnotes.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	705	705
Unresolved (see footnote)	Ordinary Shares	8,663	8,663

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,388	$239.68	Aug 8, 2034	$0
1,407	$242.85	Aug 8, 2035	$0
1,506	$238.91	Aug 10, 2036	$0

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Karen Burton

Sr. Vice Pres., CFO

8.3K

13K

no sales

Vesting, gifts, unvested awards and holding lines for Karen Burton

0shares vested or exercised

0gifted (net of own trusts)

−607withheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	8,304	12,956

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,144	$251.34	Jun 4, 2034	$0
6,944	$267.66	Jun 3, 2035	$0
8,356	$265.43	Oct 1, 2035	$0
18,564	$230.74	Jun 2, 2036	$94K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Renato Tamaro

V.P. & Corporate Treasurer

7.2K

−5K

6.2K

86%

Vesting, gifts, unvested awards and holding lines for Renato Tamaro

+3.5Kshares vested or exercised

0gifted (net of own trusts)

−251withheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	7,195	6,194

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,264	$251.34	Jun 4, 2034	$0
2,316	$267.66	Jun 3, 2035	$0
2,620	$230.74	Jun 2, 2036	$13K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Kenneth Kohler

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +2,866 shares on Jun 1, 2026 (Direct). See the filing Sales and other transactions for Kenneth Kohler are complete.

SVP & Gm, Ast

n/a

Vesting, gifts, unvested awards and holding lines for Kenneth Kohler

0shares vested or exercised

0gifted (net of own trusts)

−509withheld by the company for taxes

none reportedunvested awards, start → end

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +2,866 shares on Jun 1, 2026 (Direct). The balances below are as reported, not verified totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	6,776	11,332

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,136	$147.05	May 31, 2029	$190K
3,728	$182.22	Jun 1, 2030	$200K
2,764	$210.30	Jun 2, 2031	$70K
4,100	$250.06	Jun 2, 2032	$0
4,192	$219.97	May 31, 2033	$66K
7,900	$251.34	Jun 4, 2034	$0
6,728	$267.66	Jun 3, 2035	$0
7,668	$230.74	Jun 2, 2036	$39K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Lindsey McGowan

Minor difference of 7 shares. Difference is under 0.5% of holdings. Started reporting during the period; starting holdings are from the Form 3. An owner entity could not be identified from the footnotes.

VP, Chf. Comp. & Quality Offc.

4.5K

5.9K

no sales

Vesting, gifts, unvested awards and holding lines for Lindsey McGowan

0shares vested or exercised

0gifted (net of own trusts)

−527withheld by the company for taxes

none reportedunvested awards, start → end

Started reporting during the period; starting holdings are from the Form 3.
An owner entity could not be identified from the footnotes.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	4,230	5,656
Unresolved (see footnote)	Ordinary Shares	248	255

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,480	$219.97	May 31, 2033	$39K
2,008	$251.34	Jun 4, 2034	$0
2,056	$267.66	Jun 3, 2035	$0
4,036	$230.74	Jun 2, 2036	$20K

Estimate: options held × ($235.78 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Reconciliation: minor difference of 7 shares. Difference is under 0.5% of holdings.

Christopher Holland

Director

582

no sales

Vesting, gifts, unvested awards and holding lines for Christopher Holland

0shares vested or exercised

0gifted (net of own trusts)

5K → 6Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Ordinary Shares	582	582

18 of 19 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (17 exactly, 1 with a minor or footnoted difference). For 1 we show sales but not holdings; the ! icon on that row explains why. Percentages cover 13 of 19 officers and directors. Left out: Kenneth Kohler (holdings couldn't be fully reconciled); Nirav Shah (most holdings were last confirmed in 2021); Paul Martin, Esther Alegria, Louis Shapiro and Pierre Boulud (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$9.8M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $9.8M across 39,528 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $1.2M · 13%

87%

The lighter segment is sales with no plan disclosed in the filing ($8.6M), including tax-related sales outside a plan.

No plan disclosed · $8.6M

Sales with no 10b5-1 plan and no tax reference in the filing. $4.0M of it is John Zangerle. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: John Zangerle, Nov 11, 2025

Taxes

15,617 shares ($2.5M) were withheld by the company for taxes, which isn't a market sale.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
John Zangerle Sr. VP, Gen Counsel, and Sec.	16K	$4.3M	7%	43%	Nov 11, 2025 to Jun 15, 2026
Julia Madsen Sr. VP and GM, Life Sciences	5K	$1.3M	0%	13%	Nov 21, 2025 to Nov 21, 2025
Renato Tamaro V.P. & Corporate Treasurer	5K	$1.3M	0%	13%	Nov 18, 2025 to Nov 18, 2025
Mohsen Sohi Director	4.1K	$957K	0%	10%	Aug 12, 2026 to Aug 12, 2026
Daniel Carestio President and CEO, Director	4.4K	$947K	100%	10%	Jun 4, 2026 to Jun 5, 2026
Cynthia Feldmann Director	3.1K	$735K	0%	7%	Mar 5, 2026 to Mar 5, 2026
Richard Breeden Director	1.5K	$310K	0%	3%	Jun 2, 2026 to Jun 2, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$6.6M	$0	$0	$6.6M
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$735K	$0	$0	$735K
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$1.6M	$1.2M	$0	$310K
Jul 2026	$0	$0	$0	$0
Aug 2026	$957K	$0	$0	$957K
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about two-thirds of the 5-year average. 7 insiders sold; the average is 7 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 8, 2026 Latest 12 months	40K	7	$9.8M
Oct 8, 2025 1 year earlier	53K	7	$12.9M
Oct 8, 2024 2 years earlier	103K	9	$24.6M
Oct 9, 2023 3 years earlier	26K	5	$5.5M
Oct 9, 2022 4 years earlier	82K	6	$19.7M
Oct 9, 2021 5 years earlier	53K	8	$10.3M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty1 insider whose holdings couldn't be fully reconciled

Kenneth Kohler: holdings couldn't be fully reconciled (difference of 2,866 shares). Balance changed without a matching transaction, and the footnote does not state the amount: +2,866 shares on Jun 1, 2026 (Direct). Filing, Jun 1, 2026

Footnote: "109 shares were withheld from the 373 restricted shares that vested on June 1, 2026. These 109 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These vested shares were valued at the NYSE closing market price on June 1, 2026. | As of June 1, 2026, 3,141 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 225 on June 2, 2026; 630 on June 3, 2026; 513 on June 4, 2026; 630 on June 3, 2027; 513 on June 4, 2027 and 630 on June 5, 2028. | The shares beneficially"

Lindsey McGowan: minor difference of 7 shares. Difference is under 0.5% of holdings.

Inferred typo: the share class "Ordinary Sahres" is treated as the same class as "Ordinary Shares" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Michael Tokich, 50,565 shares): old title, new title

Inferred typo: the share class "Ordinary Share" is treated as the same class as "Ordinary Shares" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Mohsen Sohi, 22,911 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology448 filings from SEC EDGAR, and how we read them

All 448 Forms 3, 4 and 5 filed for Steris (SEC CIK 1757898) from Mar 27, 2019 to Oct 5, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (12)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Jacqueline Kosecoff	Aug 12, 2024	26,639 shares, last reported balance as of May 13, 2024
Richard Steeves	Aug 12, 2024	No balance on record
Andrew Xilas	Jun 4, 2024	6,347 shares, last reported balance as of May 31, 2024
David Lewis	Jul 22, 2021	8,245 shares, last reported balance as of Jul 21, 2021
Walter Rosebrough Jr.	Nov 10, 2020	117,406 shares, last reported balance as of Nov 9, 2020
Kathleen Bardwell	Jul 2, 2019	17,428 shares, last reported balance as of Jun 28, 2019
Michiel deZwaan	Jun 27, 2019	8,152 shares, last reported balance as of May 31, 2019
Loyal Wilson	Jun 5, 2019	24,000 shares, last reported balance as of Jun 4, 2019
Adrian Coward	Jun 3, 2019	25,119 shares, last reported balance as of May 31, 2019
Gulam Khan	Jun 3, 2019	14,685 shares, last reported balance as of May 31, 2019
Michael Wood	May 17, 2019	16,631 shares, last reported balance as of May 16, 2019
Duncan Nichol	Mar 28, 2019	No balance on record

Steris insiders sold $9.8M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Common questions

Is the Steris CEO selling stock?

Why are Steris insiders selling?

Are any Steris insiders buying?

How much of their stake did Steris insiders sell?

The evidence

No plan disclosed · $8.6M

Taxes

Sales by month